Pirfenidone (Esbriet, Pirespa)
Other Medications · Approved since 2014
Description
Pirfenidone is an anti-fibrotic agent originally approved for idiopathic pulmonary fibrosis that is being evaluated in colorectal cancer treatment as part of combination regimens. In CRC, pirfenidone is used alongside immunotherapy agents like sintilimab or anti-PD-1 antibodies, combined with standard chemotherapy or targeted agents such as fruquintinib. The drug's anti-fibrotic properties may help modify the tumor microenvironment to enhance the effectiveness of other cancer treatments, particularly in microsatellite stable (MSS) colorectal tumors.
Mechanism of Action
Pirfenidone works by inhibiting multiple pathways involved in fibrosis and inflammation, including transforming growth factor-beta (TGF- ) signaling, platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF). By reducing fibrosis in the tumor microenvironment, pirfenidone may improve immune cell infiltration and enhance the activity of immunotherapy agents in traditionally immunotherapy-resistant MSS colorectal cancers.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Esbriet, Pirespa |
| Category | Other Medications |
 Status | Off-label |
 Estado EMA | med_ema_not_submitted |
 Acceso España | med_spain_not_funded |
| Administration | Oral |
| Year Approved | 2014 |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.